Placebo-controlled trial of ketanserin in the treatment of intermittent claudication.
The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change + 12%, 95% CI -9; + 33%) or total walking time (mean change -14%, 95% CI -47%; + 19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.
Cameron
H A
HA
Waller
P C
PC
Ramsay
L E
LE
D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy / Q000503:physiopathology*; D007650:Ketanserin / Q000009:adverse effects / Q000627:therapeutic use*; D008124:Locomotion; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D007650:Ketanserin